Physician profile
Brian D Dedinsky
NPI 1730238106
$877.77
in general payments reported to CMS, 2019-2025
20 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.27 · 2020: $47.68 · 2021: $143 · 2022: $202 · 2023: $196 · 2024: $38.60 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $155.54 | 2020-2022 | |
| Amgen INC. | $127.40 | 2022-2025 | Repatha, Otezla |
| Abbott Laboratories | $96.81 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Cleerly, INC. | $72.83 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.15 | 2021-2022 | |
| Boston Scientific Corporation | $57.65 | 2023-2025 | Wavewriter Alpha Prime 16, Watchman Access System |
| Allergan, INC. | $55.58 | 2019-2020 | |
| Exact Sciences Corporation | $42.23 | 2025 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $35.16 | 2023 | |
| Intra-Sana Laboratories | $29.41 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Kowa Pharmaceuticals America, INC. | $27.86 | 2021-2022 | |
| Edwards Lifesciences Corporation | $26.05 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $17.35 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $16.94 | 2025 | |
| Abbvie INC. | $14.03 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $13.45 | 2021 | |
| Pulmonx Corporation | $13.36 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Idorsia Pharmaceuticals US INC | $12.97 | 2023 | Quviviq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dedinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.